Welcome to our dedicated page for Genix Pharmaceut news (Ticker: GENPF), a resource for investors and traders seeking the latest updates and insights on Genix Pharmaceut stock.
Genix Pharmaceuticals Corporation develops and commercializes novel and generic ophthalmic drugs, proprietary over-the-counter nutraceuticals and other single-molecule generic healthcare products. News about GENPF centers on its product-focused pharmaceutical and nutraceutical business, along with capital structure actions such as non-brokered private placements, unit financings, warrant repricing and warrant extensions tied to outstanding securities.
Company updates also cover governance and shareholder matters, including annual meeting results, director elections, auditor appointments, stock option plan approvals and related-party participation in financings.
Genix Pharmaceuticals (GENPF) corrected terms for a recently closed non‑brokered private placement announced earlier. The Company clarified the Unit issue price was $0.05 per Unit (not $0.10). The Company issued 2,000,000 Units at $0.05 for total gross proceeds of $100,000. Each Unit includes one common share and one transferable warrant. Each warrant permits purchase of one additional share at $0.10 per share and expires on September 4, 2027. All other private placement terms remain unchanged.
Genix Pharmaceuticals (TSXV: GENX) has completed a non-brokered private placement, raising $100,000 through the issuance of 2,000,000 units at $0.10 per unit. Each unit comprises one common share and one transferable warrant, with warrants exercisable at $0.10 per share until September 04, 2027.
The placement was entirely subscribed by company insiders - the President and CEO. The proceeds will be used for general working capital and potential new product funding. All securities issued are subject to a four-month hold period, and the offering completion remains subject to TSX Venture Exchange approval.
Summary not available.
Summary not available.
Summary not available.